212 related articles for article (PubMed ID: 19435820)
1. Antifolate activity of pyrimethamine enhances temozolomide-induced cytotoxicity in melanoma cells.
Chen M; Osman I; Orlow SJ
Mol Cancer Res; 2009 May; 7(5):703-12. PubMed ID: 19435820
[TBL] [Abstract][Full Text] [Related]
2. Pyrimethamine sensitizes pituitary adenomas cells to temozolomide through cathepsin B-dependent and caspase-dependent apoptotic pathways.
Dai C; Zhang B; Liu X; Guo K; Ma S; Cai F; Yang Y; Yao Y; Feng M; Bao X; Deng K; Jiao Y; Wei Z; Junji W; Xing B; Lian W; Wang R
Int J Cancer; 2013 Oct; 133(8):1982-93. PubMed ID: 23564480
[TBL] [Abstract][Full Text] [Related]
3. Temozolomide chemoresistance heterogeneity in melanoma with different treatment regimens: DNA damage accumulation contribution.
Boeckmann L; Nickel AC; Kuschal C; Schaefer A; Thoms KM; Schön MP; Thomale J; Emmert S
Melanoma Res; 2011 Jun; 21(3):206-16. PubMed ID: 21460749
[TBL] [Abstract][Full Text] [Related]
4. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.
Roos WP; Batista LF; Naumann SC; Wick W; Weller M; Menck CF; Kaina B
Oncogene; 2007 Jan; 26(2):186-97. PubMed ID: 16819506
[TBL] [Abstract][Full Text] [Related]
5. Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.
Plummer ER; Middleton MR; Jones C; Olsen A; Hickson I; McHugh P; Margison GP; McGown G; Thorncroft M; Watson AJ; Boddy AV; Calvert AH; Harris AL; Newell DR; Curtin NJ
Clin Cancer Res; 2005 May; 11(9):3402-9. PubMed ID: 15867241
[TBL] [Abstract][Full Text] [Related]
6. Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity.
Pagani E; Falcinelli S; Pepponi R; Turriziani M; Caporaso P; Caporali S; Bonmassar E; D'Atri S
Int J Oncol; 2007 Feb; 30(2):443-51. PubMed ID: 17203227
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (adp-ribose) polymerase inhibitor.
Tentori L; Portarena I; Barbarino M; Balduzzi A; Levati L; Vergati M; Biroccio A; Gold B; Lombardi ML; Graziani G
Mol Pharmacol; 2003 Jan; 63(1):192-202. PubMed ID: 12488552
[TBL] [Abstract][Full Text] [Related]
8. The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound.
Caporali S; Alvino E; Starace G; Ciomei M; Brasca MG; Levati L; Garbin A; Castiglia D; Covaciu C; Bonmassar E; D'Atri S
Pharmacol Res; 2010 May; 61(5):437-48. PubMed ID: 20026273
[TBL] [Abstract][Full Text] [Related]
9. Pyrimethamine induces apoptosis of melanoma cells via a caspase and cathepsin double-edged mechanism.
Giammarioli AM; Maselli A; Casagrande A; Gambardella L; Gallina A; Spada M; Giovannetti A; Proietti E; Malorni W; Pierdominici M
Cancer Res; 2008 Jul; 68(13):5291-300. PubMed ID: 18593930
[TBL] [Abstract][Full Text] [Related]
10. Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.
Tentori L; Portarena I; Torino F; Scerrati M; Navarra P; Graziani G
Glia; 2002 Oct; 40(1):44-54. PubMed ID: 12237842
[TBL] [Abstract][Full Text] [Related]
11. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.
Aghi M; Rabkin S; Martuza RL
J Natl Cancer Inst; 2006 Jan; 98(1):38-50. PubMed ID: 16391370
[TBL] [Abstract][Full Text] [Related]
12. Synergistic cytotoxicity of the poly (ADP-ribose) polymerase inhibitor ABT-888 and temozolomide in dual-drug targeted magnetic nanoparticles.
Muñoz-Gámez JA; López Viota J; Barrientos A; Carazo Á; Sanjuán-Nuñez L; Quiles-Perez R; Muñoz-de-Rueda P; Delgado Á; Ruiz-Extremera Á; Salmerón J
Liver Int; 2015 Apr; 35(4):1430-41. PubMed ID: 24821649
[TBL] [Abstract][Full Text] [Related]
13. Nijmegen breakage syndrome protein (NBN) causes resistance to methylating anticancer drugs such as temozolomide.
Eich M; Roos WP; Dianov GL; Digweed M; Kaina B
Mol Pharmacol; 2010 Nov; 78(5):943-51. PubMed ID: 20729302
[TBL] [Abstract][Full Text] [Related]
14. Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications.
Zhang J; Stevens MF; Laughton CA; Madhusudan S; Bradshaw TD
Oncology; 2010; 78(2):103-14. PubMed ID: 20357518
[TBL] [Abstract][Full Text] [Related]
15. Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73.
Thangasamy T; Sittadjody S; Mitchell GC; Mendoza EE; Radhakrishnan VM; Limesand KH; Burd R
BMC Cancer; 2010 Jun; 10():282. PubMed ID: 20540768
[TBL] [Abstract][Full Text] [Related]
16. In vitro antitumour activity of resveratrol in human melanoma cells sensitive or resistant to temozolomide.
Fuggetta MP; D'Atri S; Lanzilli G; Tricarico M; Cannavò E; Zambruno G; Falchetti R; Ravagnan G
Melanoma Res; 2004 Jun; 14(3):189-96. PubMed ID: 15179187
[TBL] [Abstract][Full Text] [Related]
17. Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity.
Hirose Y; Kreklau EL; Erickson LC; Berger MS; Pieper RO
J Neurosurg; 2003 Mar; 98(3):591-8. PubMed ID: 12650433
[TBL] [Abstract][Full Text] [Related]
18. Deferiprone Enhances Temozolomide Cytotoxicity in Glioma Cells.
Alexiou GA; Gerogianni P; Vartholomatos E; Kyritsis AP
Cancer Invest; 2016 Nov; 34(10):489-495. PubMed ID: 27768402
[TBL] [Abstract][Full Text] [Related]
19. Genomic and molecular profiling predicts response to temozolomide in melanoma.
Augustine CK; Yoo JS; Potti A; Yoshimoto Y; Zipfel PA; Friedman HS; Nevins JR; Ali-Osman F; Tyler DS
Clin Cancer Res; 2009 Jan; 15(2):502-10. PubMed ID: 19147755
[TBL] [Abstract][Full Text] [Related]
20. Parthenolide enhances dacarbazine activity against melanoma cells.
Koprowska K; Hartman ML; Sztiller-Sikorska M; Czyz ME
Anticancer Drugs; 2013 Sep; 24(8):835-45. PubMed ID: 23797801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
